Hepatology

Metabolic Dysfunction-Associated Liver Diseases

Questions discussed in this category

If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?

2 Answers available

Given that cardiovascular disease is the top cause of morbidity/mortality in patients with MASLD, do you perform any additional screening and/or testing for these patients to minimize this impact?

1 Answer available

In patients with Met-ALD, how do you approach their treatment plan?

Do you tackle the alcohol first over the metabolic comorbidities?

1 Answer available

In patients with Met-ALD, would you still offer the same therapeutic/pharmacologic treatments (ex: GIP/GLP-1 agonists, Resmetirom, ex) for management of their disease as in a "pure" MASLD patient?

1 Answer available

In patients with MASLD and F2–F3 fibrosis, would you initiate Resmetirom even if they are not making active lifestyle changes?

And for how long?

3 Answers available

How do you choose between resmetirom and semaglutide in the treatment of MASH?

1 Answer available

Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?

3 Answers available

How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?

2 Answers available

How do you incorporate other pharmacologic bariatric/appetite suppressants in the context of their clinical care plan for MASLD?

1 Answer available

What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?

1 Answer available

How do you approach a patient's candidacy for simultaneous liver transplant and bariatric surgery if MASLD is the etiology of their end-stage liver disease?

1 Answer available

How does presence of clinically significant portal hypertension change patient prognosis in MASLD?

1 Answer available

Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?

1 Answer available

Papers discussed in this category

Lancet (London, England), 2015-03-14

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

The New England journal of medicine, 2020 Nov 13

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Gastroenterology, 2015 Apr 10

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

The New England journal of medicine, 2010 Apr 28

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Hepatology (Baltimore, Md.), 2022 Jan 24

Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021 Jun 04

The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained.

The New England journal of medicine, 2024 Feb 08

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

Hepatology (Baltimore, Md.), 2024 Oct 18

Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.

International journal of molecular sciences, 2022 Mar 13

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.

Hepatology

Metabolic Dysfunction-Associated Liver Diseases

Questions discussed in this category

Papers discussed in this category

Related Topics in Hepatology